Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.

8 Similarly, an Italian retrospective study including 101 patients showed that the 6-month cut-off for the TFI appeared to have prognostic value but the result did not reach statistical significance. 12 Median OS was 48.3 and 29.5 months for patients with a TFI of more and less than 6 months, respectively (HR 0.73; 95% CI 0.39–1.37; p=0.331). 12 With a larger sample size, our analysis shows the important prognostic role of TFI with an almost 11-month absolute median OS advantage (18.4 vs 29.3 months) for patients relapsing >12 months following completion of adjuvant trastuzumab (adjusted HR 0.69; 95% CI 0.54–0.89; p=0.004).

also in 111,027 other papers